COVID-19 Vaccine Choice May Matter for Older Adults, VA Data Suggest

A VA study found that Moderna's mRNA-1283 vaccine reduced COVID-19 risk by 35.9% and hospitalizations by 47% compared to Pfizer-BioNTech's BNT162b2 in veterans 65+. The study analyzed 294,000+ veterans, showing mRNA-1283's sustained durability and cardiovascular benefits. Researchers attributed the differences to mRNA-1283's targeted immune response. The findings may influence seasonal vaccine decisions for high-risk populations.

Original reporting
Published Nov 21, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 3:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
COVID-19 Vaccine Choice May Matter for Older Adults, VA Data Suggest — source image
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The study provides first‑time real‑world effectiveness data that could shift market expectations for both companies' COVID‑19 vaccine revenues and future contracts.

02

Market read

First‑report of comparative vaccine effectiveness may influence investor sentiment toward Moderna and Pfizer, affecting biotech sector dynamics.

03

What to watch

Supply chain constraints, pricing negotiations with governments, and upcoming FDA authorizations could moderate the impact of the efficacy gap.

Relevance 8/10Novelty 9/10Timing: today

Background

A VA study of over 294,000 veterans 65+ compares Moderna's mRNA-1283 and Pfizer's BNT162b2, finding significant reductions in COVID‑19 risk and hospitalizations for the Moderna vaccine.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

VA cohort study shows Moderna's mRNA-1283 cuts COVID-19 risk 35.9% versus Pfizer's BNT162b2.

Expected impact

likely upward pressure as market prices in superior efficacy.

Evidence & confidence

First‑report of real‑world effectiveness gives Moderna a competitive edge, potentially increasing sales and contracts.

$PFEBearishHigh confidence
Context

VA cohort study finds Pfizer's BNT162b2 less effective than Moderna's mRNA-1283 in older veterans.

Expected impact

likely downward pressure as investors reassess Pfizer's vaccine prospects.

Evidence & confidence

First‑report of comparative effectiveness may dampen expectations for Pfizer's COVID‑19 vaccine sales.

Market effects

Boosts biotech/vaccine sector favoring Moderna, puts pressure on Pfizer and other COVID‑19 vaccine makers.

US market may react as VA data influences domestic vaccine procurement and investor sentiment.

New effectiveness data could affect global COVID‑19 vaccine demand and competitive dynamics.

Counterpoint

Pfizer may benefit if the data spurs additional booster campaigns or if regulatory bodies favor its broader safety record.

Key entities

  • Moderna Inc.

    Developer of the mRNA-1283 COVID‑19 vaccine.

  • Pfizer Inc.

    Manufacturer of the BNT162b2 (Comirnaty) COVID‑19 vaccine.

  • U.S. Department of Veterans Affairs

    Conducted the cohort study on vaccine effectiveness.

Related articles

$PFEHigh

Blackstone Life Sciences Funds Pfizer's Obesity Drug Program

Blackstone Life Sciences will invest $1.5B in Pfizer's obesity drug program, funding 10 Phase 3 trials for berobenatide. Pfizer acquired the drug via a $10B purchase of Metsera. Blackstone's funding will support large-scale trials through 2028, with Pfizer paying milestones upon FDA approval. Pfizer aims to strengthen its position in the obesity drug market.

$MRNAMedAI 8/10

A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and…

A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and hospitalization risk by 47.0% compared to Pfizer/BioNTech's BNT162b2 in older veterans during the 2025-2026 season. The study included 294,499 participants, with mRNA-1283 showing better outcomes across various metrics. Moderna supported the study, which was conducted by independent investigators.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.